Novartis MS drug cuts relapse rate by half compared to Sanofi medicine

ZURICH (Reuters) – Novartis’s investigational multiple sclerosis drug ofatumumab cut the relapse rate in patients by more than half in trials comparing it to Sanofi’s Aubagio as the Swiss drugmaker aims to refresh its portfolio of medicines in neurological diseases. Patients getting ofatumumab had an annualised relapse rate that corresponded to a reduction of 50.5% in one study and 58.8% in another, Novartis said in a statement on Friday. While Novartis’s study compared its medicine with Sanofi’s, the Basel-based company is hoping ofatumumab will challenge Roche’s star MS drug Ocrevus. Novartis plans to start asking health authorities for approvals by year’s end.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s